1887

Abstract

The zoonotic emerging Rift Valley fever virus (RVFV) causes sporadic disease in livestock and humans throughout Africa and the Saudi Arabian peninsula. Infection of people with RVFV can occur through mosquito bite or mucosal exposure during butchering or milking of infected livestock. Disease typically presents as a self-limiting fever; however, in rare cases, hepatitis, encephalitis and ocular disease may occur. Recent studies have illuminated the neuropathogenic mechanisms of RVFV in a rat aerosol infection model. Neurological disease in rats is characterized by breakdown of the blood–brain barrier late in infection, infiltration of leukocytes to the central nervous system (CNS) and massive viral replication in the brain. However, the route of RVFV entry into the CNS after inhalational exposure remains unknown. Here, we visualized the entire nasal olfactory route from snout to brain after RVFV infection using RNA hybridization and immunofluorescence microscopy. We found widespread RVFV-infected cells within the olfactory epithelium, across the cribriform plate, and in the glomerular region of the olfactory bulb within 2 days of infection. These results indicate that the olfactory tract is a major route of infection of the brain after inhalational exposure. A better understanding of potential neuroinvasion pathways can support the design of more effective therapeutic regiments for the treatment of neurological disease caused by RVFV.

Funding
This study was supported by the:
  • National Institute of Allergy and Infectious Diseases (Award T32 AI060525)
    • Principle Award Recipient: Cynthia M McMillen
  • National Institute of Neurological Disorders and Stroke (Award R21NS088326)
    • Principle Award Recipient: Amy L Hartman
  • National Institute of Neurological Disorders and Stroke (Award R01NS101100)
    • Principle Award Recipient: Amy L Hartman
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001522
2020-11-24
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/102/2/vir001522.html?itemId=/content/journal/jgv/10.1099/jgv.0.001522&mimeType=html&fmt=ahah

References

  1. Davies FG, Martin V. Recognizing Rift Valley Fever. FAO Animal Health manual Food and Agriculture Organization of the United Nations. Volume 17. Available at: http://www.fao.org/3/y4611e/y4611e00.htm ; 2003
  2. McIntosh BM, Russell D, dos Santos I, Gear JH. Rift Valley fever in humans in South Africa. S Afr Med J 1980; 58:803–806[PubMed]
    [Google Scholar]
  3. Al-Hazmi A, Al-Rajhi AA, Abboud EB, Ayoola EA, Al-Hazmi M et al. Ocular complications of Rift Valley fever outbreak in Saudi Arabia. Ophthalmology 2005; 112:313–318 [View Article][PubMed]
    [Google Scholar]
  4. Laughlin LW, Meegan JM, Strausbaugh LJ, Morens DM, Watten RH. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Trans R Soc Trop Med Hyg 1979; 73:630–633 [View Article][PubMed]
    [Google Scholar]
  5. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003; 37:1084–1092 [View Article][PubMed]
    [Google Scholar]
  6. Strausbaugh LJ, Laughlin LW, Meegan JM, Watten RH. Clinical studies on Rift Valley fever, part I: acute febrile and hemorrhagic-like diseases. J Egypt Public Health Assoc 1978; 53:181–182[PubMed]
    [Google Scholar]
  7. Abdel-Wahab KS, El Baz LM, El-Tayeb EM, Omar H, Ossman MA et al. Rift Valley fever virus infections in Egypt: pathological and virological findings in man. Trans R Soc Trop Med Hyg 1978; 72:392–396 [View Article][PubMed]
    [Google Scholar]
  8. LaBeaud AD, Pfeil S, Muiruri S, Dahir S, Sutherland LJ et al. Factors associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya. PLoS Negl Trop Dis 2015; 9:e0003548 [View Article][PubMed]
    [Google Scholar]
  9. Anyangu AS, Gould LH, Sharif SK, Nguku PM, Omolo JO et al. Risk factors for severe Rift Valley fever infection in Kenya, 2007. Am J Trop Med Hyg 2010; 83:14–21 [View Article][PubMed]
    [Google Scholar]
  10. Nicholas DE, Jacobsen KH, Waters NM. Risk factors associated with human Rift Valley fever infection: systematic review and meta-analysis. Trop Med Int Health 2014; 19:1420–1429 [View Article][PubMed]
    [Google Scholar]
  11. Hoogstraal H, Meegan JM, Khalil GM, Adham FK. The Rift Valley fever epizootic in Egypt 1977-78. 2. ecological and entomological studies. Trans R Soc Trop Med Hyg 1979; 73:624–629 [View Article][PubMed]
    [Google Scholar]
  12. Hartman AL, Powell DS, Bethel LM, Caroline AL, Schmid RJ et al. Aerosolized Rift Valley fever virus causes fatal encephalitis in African green monkeys and common marmosets. J Virol 2014; 88:2235–2245 [View Article][PubMed]
    [Google Scholar]
  13. Wonderlich ER, Caroline AL, McMillen CM, Walters AW, Reed DS et al. Peripheral blood biomarkers of disease outcome in a monkey model of Rift Valley fever encephalitis. J Virol 2018; 92: 01 02 2018 [View Article][PubMed]
    [Google Scholar]
  14. Smith DR, Bird BH, Lewis B, Johnston SC, McCarthy S et al. Development of a novel nonhuman primate model for Rift Valley fever. J Virol 2012; 86:2109–2120 [View Article][PubMed]
    [Google Scholar]
  15. Hickerson BT, Westover JB, Van Wettere AJ, Rigas JD, Miao J et al. Pathogenesis of Rift Valley fever virus aerosol infection in STAT2 knockout hamsters. Viruses 2018; 10:651 19 11 2018 [View Article][PubMed]
    [Google Scholar]
  16. Scharton D, Bailey KW, Vest Z, Westover JB, Kumaki Y et al. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res 2014; 104:84–92 [View Article]
    [Google Scholar]
  17. Reed C, Lin K, Wilhelmsen C, Friedrich B, Nalca A et al. Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development. PLoS Negl Trop Dis 2013; 7:e2156 [View Article]
    [Google Scholar]
  18. Dodd KA, McElroy AK, Jones TL, Zaki SR, Nichol ST et al. Rift Valley fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model. PLoS Negl Trop Dis 2014; 8:e2874 [View Article]
    [Google Scholar]
  19. Albe JR, Boyles DA, Walters AW, Kujawa MR, McMillen CM et al. Neutrophil and macrophage influx into the central nervous system are inflammatory components of lethal Rift Valley fever encephalitis in rats. PLoS Pathog 2019; 15:e1007833-e [View Article]
    [Google Scholar]
  20. Walters AW, Kujawa MR, Albe JR, Reed DS, Klimstra WB et al. Vascular permeability in the brain is a late pathogenic event during Rift Valley fever virus encephalitis in rats. Virology 2019; 526:173–179 [View Article]
    [Google Scholar]
  21. van Velden DJ, Meyer JD, Olivier J, Gear JH, McIntosh B. Rift Valley fever affecting humans in South Africa: a clinicopathological study. S Afr Med J 1977; 51:867–871
    [Google Scholar]
  22. Esiri MM. Herpes simplex encephalitis: an immunohistological study of the distribution of viral antigen within the brain. J Neurol Sci 1982; 54:209–226
    [Google Scholar]
  23. Smith GA, Gross SP, Enquist LW. Herpesviruses use bidirectional fast-axonal transport to spread in sensory neurons. Proc Natl Acad Sci U S A 2001; 98:3466–3470 [View Article]
    [Google Scholar]
  24. Munster VJ, Prescott JB, Bushmaker T, Long D, Rosenke R et al. Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route. Sci Rep 2012; 2:736 [View Article]
    [Google Scholar]
  25. Bennett RS, Cress CM, Ward JM, Firestone C-Y, Murphy BR et al. Pathogenesis, and immunogenicity in mice and monkeys. Virol J 2008; 5:25
    [Google Scholar]
  26. Casiraghi C, Dorovini-Zis K, Horwitz MS. Epstein-Barr virus infection of human brain microvessel endothelial cells: a novel role in multiple sclerosis. J Neuroimmunol 2011; 230:173–177 [View Article]
    [Google Scholar]
  27. Clay CC, Rodrigues DS, Ho YS, Fallert BA, Janatpour K et al. Neuroinvasion of Fluorescein-Positive monocytes in acute simian immunodeficiency virus infection. J Virol 2007; 81:12040–12048 [View Article]
    [Google Scholar]
  28. Faber HK, Silverberg RJ, Dong L. Poliomyelitis in the cynomolgus monkey: iii. infection by inhalation of droplet nuclei and the nasopharyngeal portal of entry, with a note on this mode of infection in rhesus. J Exp Med 1944; 80:39–57
    [Google Scholar]
  29. Crotty S, Hix L, Sigal LJ, Andino R. Poliovirus pathogenesis in a new poliovirus receptor transgenic mouse model: age-dependent paralysis and a mucosal route of infection. J Gen Virol 2002; 83:1707–1720 [View Article]
    [Google Scholar]
  30. Shope RE. Bunyaviruses. Medical Microbiology Galveston, TX: The University of Texas Medical Branch at Galveston; 1996
    [Google Scholar]
  31. Bales JM, Powell DS, Bethel LM, Reed DS, Hartman AL. Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley fever virus. Front Cell Infect Microbiol 2012; 2:105 [View Article]
    [Google Scholar]
  32. Alers JC, Krijtenburg P-J, Vissers KJ, van Dekken H. Effect of bone decalcification procedures on DNA in situ hybridization and comparative genomic hybridization: EDTA is highly preferable to a routinely used acid Decalcifier. J Histochem Cytochem 1999; 47:703–709 [View Article]
    [Google Scholar]
  33. Abu-Elyazeed R, el-Sharkawy S, Olson J, Botros B, Soliman A et al. Prevalence of anti-Rift-Valley-fever IgM antibody in abattoir workers in the Nile delta during the 1993 outbreak in Egypt. Bull World Health Organ 1996; 74:155–158
    [Google Scholar]
  34. Turkistany AH, Mohamed AG, Al-Hamdan N. Seroprevalence of Rift Valley fever among slaughterhouse personnel in Makkah during hajj 1419h (1999). J Fam Community Health 2001; 8:53–57
    [Google Scholar]
  35. Chambers PG, Swanepoel R. Rift valley fever in abattoir workers. Cent Afr J Med 1980; 26:122–126
    [Google Scholar]
  36. Smithburn KC, Mahaffy AF, Haddow AJ, Kitchen SF, Smith JF. Rift Valley fever; accidental infections among laboratory workers. J Immunol 1949; 62:213–227
    [Google Scholar]
  37. Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS et al. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley fever. PLoS Negl Trop Dis 2014; 8:e2790 [View Article]
    [Google Scholar]
  38. Morrill JC, Jennings GB, Johnson AJ, Cosgriff TM, Gibbs PH et al. Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch Virol 1990; 110:195–212 [View Article]
    [Google Scholar]
  39. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287:2391–2405
    [Google Scholar]
  40. Miller WS, Demciiak P, Rosenberger CR, Dominik JW, Bradshaw JL. Stability and infectivity of airborne yellow fever and Rift Valley fever viruses. Am J Hyg 1963; 77:114–121
    [Google Scholar]
  41. Sidwell RW, Smee DF. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res 2003; 57:101–111 [View Article]
    [Google Scholar]
  42. Caroline AL, Kujawa MR, Oury TD, Reed DS, Hartman AL. Inflammatory biomarkers associated with lethal Rift Valley fever encephalitis in the Lewis rat model. Front Microbiol 2016; 6: [View Article]
    [Google Scholar]
  43. Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol 2006; 34:252–269 [View Article]
    [Google Scholar]
  44. Escada P. [Localization and distribution of human olfactory mucosa in the nasal cavities]. Acta Med Port 2013; 26:200–207
    [Google Scholar]
  45. Gross EA, Swenberg JA, Fields S, Popp JA. Comparative morphometry of the nasal cavity in rats and mice. J Anat 1982; 135:83–88
    [Google Scholar]
  46. van Riel D, Leijten LM, Verdijk RM, GeurtsvanKessel C, van der Vries E et al. Evidence for influenza virus CNS invasion along the olfactory route in an immunocompromised infant. J Infect Dis 2014; 210:419–423 [View Article]
    [Google Scholar]
  47. Harberts E, Yao K, Wohler JE, Maric D, Ohayon J et al. Human herpesvirus-6 entry into the central nervous system through the olfactory pathway. Proc Natl Acad Sci U S A 2011; 108:13734–13739 [View Article]
    [Google Scholar]
  48. Faber HK, Silverberg RJ. A neuropathological study of acute human Polio-myelitis with special reference to the initial lesion and to various potential portals of entry. J Exp Med 1946; 83:329–353 [View Article]
    [Google Scholar]
  49. Sjölinder H, Jonsson A-B. Olfactory nerve-a novel invasion route of Neisseria meningitidis to reach the meninges. PLoS One 2010; 5:e14034-e [View Article]
    [Google Scholar]
  50. Pägelow D, Chhatbar C, Beineke A, Liu X, Nerlich A et al. The olfactory epithelium as a port of entry in neonatal neurolisteriosis. Nat Commun 2018; 9:4269 [View Article]
    [Google Scholar]
  51. Moseman EA. Mucosal immune mediated protection of the CNS following olfactory viral infection. J Immunol Res 2019; 202:66.7–7
    [Google Scholar]
  52. Soler ZM, Patel ZM, Turner JH, Holbrook EH. A primer on viral‐associated olfactory loss in the era of COVID‐19. Int Forum Allergy Rhinol 2020; 10:814–820 [View Article]
    [Google Scholar]
  53. Mori I, Nishiyama Y, Yokochi T, Kimura Y. Olfactory transmission of neurotropic viruses. J Neurovirol 2005; 11:129–137 [View Article]
    [Google Scholar]
  54. Williams SK, Franklin RJM, Barnett SC. Response of olfactory ensheathing cells to the degeneration and regeneration of the peripheral olfactory system and the involvement of the neuregulins. J Comp Neurol 2004; 470:50–62 [View Article]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001522
Loading
/content/journal/jgv/10.1099/jgv.0.001522
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error